Advancements in engineered mesenchymal stem cell exosomes for chronic lung disease treatment

Zhai, Zhengyao; Cui, Tairong; Chen, Jialiang; Mao, Xulong; Zhang, Ting

doi:10.1186/s12967-023-04729-9

Cited by 3 publications

(3 citation statements)

References 88 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antifibrotic actions of MSC-exos are particularly relevant in combating pulmonary fibrosis, characterized by excessive extracellular matrix deposition and impaired lung function [ 193 ]. MSC-exo-derived miRNAs, including miR-29b-3p and miR-186, target fibrosis-related pathways such as the frizzled 6 (FZD6) and SRY-related HMG-box 4 (SOX4)/dickkopf 1 (DKK1) pathways, respectively [ 193 ]. By inhibiting fibroblast activation and collagen synthesis, these miRNAs prevent the progression of fibrotic changes in the lung, showcasing the antifibrotic potential of MSC-exos [ 191 ].…”

Section: Potential Therapeutic Applications In Disease and Regenerati...mentioning

confidence: 99%

Therapeutic Applications of Stem Cell-Derived Exosomes

Abdulmalek,

Husain,

AlKhalifa

et al. 2024

IJMS

View full text Add to dashboard Cite

Exosomes are extracellular vesicles of endosomal origin, ranging from 30 to 150 nm in diameter, that mediate intercellular transfer of various biomolecules, such as proteins, lipids, nucleic acids, and metabolites. They modulate the functions of recipient cells and participate in diverse physiological and pathological processes, such as immune responses, cell–cell communication, carcinogenesis, and viral infection. Stem cells (SCs) are pluripotent or multipotent cells that can differentiate into various cell types. SCs can also secrete exosomes, which exhibit remarkable therapeutic potential for various diseases, especially in the field of regenerative medicine. For example, exosomes derived from mesenchymal stem cells (MSCs) contain proteins, lipids, and miRNAs that can ameliorate endocrine disorders, such as diabetes and cancer. Exosomes from SCs (sc-exos) may offer similar advantages as SCs, but with reduced risks and challenges. Sc-exos have lower tumorigenicity, immunogenicity, and infectivity. They can also deliver drugs more efficiently and penetrate deeper into tissues. In this review, we provide an overview of the recent advances in sc-exos and their therapeutic applications in various diseases, such as diabetes and cancer. We also elucidate how the biological effects of sc-exos depend on their molecular composition. We also address the current challenges and future directions of using sc-exos.

show abstract

Section: Potential Therapeutic Applications In Disease and Regenerati...mentioning

confidence: 99%

Therapeutic Applications of Stem Cell-Derived Exosomes

Abdulmalek,

Husain,

AlKhalifa

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…In addition, exosomes can be engineered to enhance their cellular targeting and therapeutic effects. 54 Liu et al 55 constructed a biomimetic nanocarrier based on exosomes and enhanced the targeting ability of the nanocarrier by fusing serum exosomes and liposomes while engineering modifications to them. The results showed that the nanocarrier could target macrophages in the lungs, reduce the inflammatory response, and promote the repair of lung injury by remodeling the immune homeostasis.…”

Section: Nano-drug Delivery Systems: Nano-formulationsmentioning

confidence: 99%

Opportunities and Challenges for Inhalable Nanomedicine Formulations in Respiratory Diseases: A Review

Feng,

Shi,

Zhang

et al. 2024

IJN

View full text Add to dashboard Cite

Lungs experience frequent interactions with the external environment and have an abundant supply of blood; therefore, they are susceptible to invasion by pathogenic microorganisms and tumor cells. However, the limited pharmacokinetics of conventional drugs in the lungs poses a clinical challenge. The emergence of different nano-formulations has been facilitated by advancements in nanotechnology. Inhaled nanomedicines exhibit better targeting and prolonged therapeutic effects. Although nano-formulations have great potential, they still present several unknown risks. Herein, we review the (1) physiological anatomy of the lungs and their biological barriers, (2) pharmacokinetics and toxicology of nanomaterial formulations in the lungs; (3) current nanomaterials that can be applied to the respiratory system and related design strategies, and (4) current applications of inhaled nanomaterials in treating respiratory disorders, vaccine design, and imaging detection based on the characteristics of different nanomaterials. Finally, (5) we analyze and summarize the challenges and prospects of nanomaterials for respiratory disease applications. We believe that nanomaterials, particularly inhaled nano-formulations, have excellent prospects for application in respiratory diseases. However, we emphasize that the simultaneous toxic side effects of biological nanomaterials must be considered during the application of these emerging medicines. This study aims to offer comprehensive guidelines and valuable insights for conducting research on nanomaterials in the domain of the respiratory system.

show abstract

“…Exosomes, particularly mesenchymal stem cell-derived exosomes, have been increasingly investigated for the treatment of pulmonary diseases, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and pulmonary fibrosis [ 5 ]. The therapeutic impact of mesenchymal stem cell-derived exosomes is largely believed to be related to anti-inflammatory, antioxidant, and anti-apoptotic effects [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Pulmonary Biodistribution of Platelet-Derived Regenerative Exosomes in a Porcine Model

Rizzo,

Bagwell,

Schiebel

et al. 2024

IJMS

View full text Add to dashboard Cite

The purpose of this study was to evaluate the biodistribution of a platelet-derived exosome product (PEP), previously shown to promote regeneration in the setting of wound healing, in a porcine model delivered through various approaches. Exosomes were labeled with DiR far-red lipophilic dye to track and quantify exosomes in tissue, following delivery via intravenous, pulmonary artery balloon catheter, or nebulization in sus scrofa domestic pigs. Following euthanasia, far-red dye was detected by Xenogen IVUS imaging, while exosomal protein CD63 was detected by Western blot and immunohistochemistry. Nebulization and intravenous delivery both resulted in global uptake of exosomes within the lung parenchyma. However, nebulization resulted in the greatest degree of exosome uptake. Pulmonary artery balloon catheter-guided delivery provided the further ability to localize pulmonary delivery. No off-target absorption was noted in the heart, spleen, or kidney. However, the liver demonstrated uptake primarily in nebulization-treated animals. Nebulization also resulted in uptake in the trachea, without significant absorption in the esophagus. Overall, this study demonstrated the feasibility of pulmonary delivery of exosomes using nebulization or intravenous infusion to accomplish global delivery or pulmonary artery balloon catheter-guided delivery for localized delivery.

show abstract

Advancements in engineered mesenchymal stem cell exosomes for chronic lung disease treatment

Cited by 3 publications

References 88 publications

Therapeutic Applications of Stem Cell-Derived Exosomes

Therapeutic Applications of Stem Cell-Derived Exosomes

Opportunities and Challenges for Inhalable Nanomedicine Formulations in Respiratory Diseases: A Review

Pulmonary Biodistribution of Platelet-Derived Regenerative Exosomes in a Porcine Model

Contact Info

Product

Resources

About